363 related articles for article (PubMed ID: 1886191)
1. Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
Steinherz LJ; Steinherz PG; Tan CT; Heller G; Murphy ML
JAMA; 1991 Sep; 266(12):1672-7. PubMed ID: 1886191
[TBL] [Abstract][Full Text] [Related]
2. Cardiac function in Wilms' tumor survivors.
Sorensen K; Levitt G; Sebag-Montefiore D; Bull C; Sullivan I
J Clin Oncol; 1995 Jul; 13(7):1546-56. PubMed ID: 7602343
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline-induced cardiac toxicity more likely in underweight childhood cancer survivors.
Andolina JR; Dilley K
J Pediatr Hematol Oncol; 2010 Jul; 32(5):411-5. PubMed ID: 20495481
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.
Brown TR; Vijarnsorn C; Potts J; Milner R; Sandor GG; Fryer C
Pediatr Blood Cancer; 2013 May; 60(5):842-8. PubMed ID: 23382019
[TBL] [Abstract][Full Text] [Related]
5. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients.
Steinherz LJ; Steinherz PG; Tan C
Med Pediatr Oncol; 1995 Jun; 24(6):352-61. PubMed ID: 7715541
[TBL] [Abstract][Full Text] [Related]
6. Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.
Sieswerda E; Kremer LC; Vidmar S; De Bruin ML; Smibert E; Sjöberg G; Cheung MM; Weintraub RG
Pediatr Blood Cancer; 2010 Apr; 54(4):579-84. PubMed ID: 20014238
[TBL] [Abstract][Full Text] [Related]
7. Echocardiographic evaluation of patients cured of childhood cancer: a single center study of 117 subjects who received anthracyclines.
Bossi G; Lanzarini L; Laudisa ML; Klersy C; Raisaro A; Aricò M
Med Pediatr Oncol; 2001 Jun; 36(6):593-600. PubMed ID: 11344489
[TBL] [Abstract][Full Text] [Related]
8. [High-resolution electrocardiography in monitoring myocardial damage after therapy with anthracyclines in children].
Mladosievicová B; Foltinová A; Bernadic M; Petrásová H; Hulín I
Bratisl Lek Listy; 1996 May; 97(5):289-97. PubMed ID: 8705327
[TBL] [Abstract][Full Text] [Related]
9. Late cardiotoxicity after treatment for a malignant bone tumor.
Postma A; Bink-Boelkens MT; Beaufort-Krol GC; Kengen RA; Elzenga NJ; Schasfoort-van Leeuwen MJ; Schraffordt koops H; Kamps WA
Med Pediatr Oncol; 1996 Apr; 26(4):230-7. PubMed ID: 8600333
[TBL] [Abstract][Full Text] [Related]
10. [The role of dobutamine stress echocardiography in early diagnosis of cardiac toxicity in long-term survivors of asymptomatic children treated with anthracycline].
Yildirim A; Tunaoğlu FS; Pinarli FG; Ilhan M; Oğuz A; Karadeniz C; Olguntürk R; Oğuz D; Kula S
Anadolu Kardiyol Derg; 2010 Apr; 10(2):154-62. PubMed ID: 20382616
[TBL] [Abstract][Full Text] [Related]
11. Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy.
Leger K; Slone T; Lemler M; Leonard D; Cochran C; Bowman WP; Bashore L; Winick N
Pediatr Blood Cancer; 2015 Jan; 62(1):123-7. PubMed ID: 25176022
[TBL] [Abstract][Full Text] [Related]
12. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy.
Toro-Salazar OH; Gillan E; O'Loughlin MT; Burke GS; Ferranti J; Stainsby J; Liang B; Mazur W; Raman SV; Hor KN
Circ Cardiovasc Imaging; 2013 Nov; 6(6):873-80. PubMed ID: 24097420
[TBL] [Abstract][Full Text] [Related]
13. Regional cardiac wall motion abnormalities during and shortly after anthracyclines therapy.
Kapusta L; Groot-Loonen J; Thijssen JM; DeGraaf R; Daniëls O
Med Pediatr Oncol; 2003 Nov; 41(5):426-35. PubMed ID: 14515381
[TBL] [Abstract][Full Text] [Related]
14. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.
van Dalen EC; van der Pal HJ; Kok WE; Caron HN; Kremer LC
Eur J Cancer; 2006 Dec; 42(18):3191-8. PubMed ID: 16987655
[TBL] [Abstract][Full Text] [Related]
15. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children.
Aggarwal S; Pettersen MD; Bhambhani K; Gurczynski J; Thomas R; L'Ecuyer T
Pediatr Blood Cancer; 2007 Nov; 49(6):812-6. PubMed ID: 17171687
[TBL] [Abstract][Full Text] [Related]
16. High risk of symptomatic cardiac events in childhood cancer survivors.
van der Pal HJ; van Dalen EC; van Delden E; van Dijk IW; Kok WE; Geskus RB; Sieswerda E; Oldenburger F; Koning CC; van Leeuwen FE; Caron HN; Kremer LC
J Clin Oncol; 2012 May; 30(13):1429-37. PubMed ID: 22473161
[TBL] [Abstract][Full Text] [Related]
17. Is screening for abnormal ECG patterns justified in long-term follow-up of childhood cancer survivors treated with anthracyclines?
Pourier MS; Mavinkurve-Groothuis AM; Loonen J; Bökkerink JP; Roeleveld N; Beer G; Bellersen L; Kapusta L
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27654133
[TBL] [Abstract][Full Text] [Related]
18. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults.
Larsen RL; Jakacki RI; Vetter VL; Meadows AT; Silber JH; Barber G
Am J Cardiol; 1992 Jul; 70(1):73-7. PubMed ID: 1615874
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
Creutzig U; Diekamp S; Zimmermann M; Reinhardt D
Pediatr Blood Cancer; 2007 Jun; 48(7):651-62. PubMed ID: 17183582
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors.
Hudson MM; Rai SN; Nunez C; Merchant TE; Marina NM; Zalamea N; Cox C; Phipps S; Pompeu R; Rosenthal D
J Clin Oncol; 2007 Aug; 25(24):3635-43. PubMed ID: 17704413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
